论文部分内容阅读
目的:研究不同剂量埃索美拉唑的三联疗法根治幽门螺杆菌的临床疗效。方法:选取2012年12月到2014年12月我院收治的幽门螺杆菌阳性胃炎患者100例,按照随机数字表法将患者分为高剂量组(n=50)和低剂量组(n=50),低剂量组给予阿莫西林(1 g/次)+克拉霉素(0.5 g/次)+埃索美拉唑(20 mg/次)治疗,而高剂量组埃索美拉唑改为40 mg/次,疗程均1个月。比较两组幽门螺杆菌清除率,及治疗前后发生反酸、上腹痛和腹胀的临床症状评分以及治疗后不良反应发生情况。结果:高剂量组患者的幽门螺杆菌清除率为92.0%,显著高于低剂量组的70.0%(P<0.05);治疗后两组临床症状评分均显著低于治疗前(P<0.05),且高剂量组显著低于低剂量组(P<0.05);两组不良反应发生率比较差异无统计学意义(P>0.05)。结论:高剂量较低剂量埃索美拉唑三联疗法能更有效根除幽门螺杆菌,改善患者的临床症状,且不会增加不良反应,值得在临床上借鉴。
Objective: To study the clinical efficacy of triple-dose esomeprazole in the treatment of H. pylori. Methods: One hundred patients with Helicobacter pylori positive gastritis admitted from December 2012 to December 2014 in our hospital were divided into high dose group (n = 50) and low dose group (n = 50) according to random number table ), Low-dose amoxicillin (1 g / time) + clarithromycin (0.5 g / time) + esomeprazole (20 mg / time) treatment, and high-dose group of esomeprazole changed 40 mg / time, treatment for 1 month. Helicobacter pylori eradication rates were compared between the two groups, and the clinical symptom scores of acid reflux, upper abdominal pain and abdominal distension occurred before and after treatment and the incidence of adverse reactions after treatment. Results: The H. pylori clearance rate was 92.0% in the high-dose group, which was significantly higher than that in the low-dose group (70.0%, P <0.05). The clinical symptom scores of the two groups were significantly lower than those before treatment (P <0.05) And high-dose group was significantly lower than the low-dose group (P <0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P> 0.05). Conclusion: The high-dose and low-dose esomeprazole triple therapy can effectively eradicate Helicobacter pylori and improve the clinical symptoms of patients without increasing adverse reactions, which is worth to be used clinically.